Castelion's $1.05B Series C: Why Carlyle and JPMorgan Are Now Co-Leading Venture Defense Rounds

TL;DR: On August 19, 2026, hypersonic missile startup Castelion closed a $1.05 billion Series C — structured as $800 million in equity plus a $250 million revolving credit facility — at a $13 billion post-money valuation. The round was co-led by Carlyle Group, JPMorgan Chase's Strategic Investment Group, and Andreessen Horowitz. When a buyout firm managing $475 billion in assets and the largest U.S. bank both co-lead a four-year-old startup's venture round, something structural has shifted in how institutional capital thinks about defense technology.

The Deal Structure: What $1.05 Billion Actually Looks Like

Most venture rounds are simple: a startup sells equity, investors get shares, everyone moves on. Castelion's Series C is not that. The round splits into $800 million of straight equity and a $250 million revolving credit facility , essentially a corporate line of credit attached to a startup's funding announcement. That structure is borrowed from private equity playbooks, not venture capital ones.

A revolving credit facility (the "revolver") lets a company draw down, repay, and re-draw capital up to a set limit as working capital demands fluctuate. For a company building physical hypersonic missiles at scale , procuring specialty materials, staffing a 1,000-acre manufacturing campus in Sandoval County, New Mexico called Project Ranger , cash timing matters in ways that software companies never face. You can't ship a missile on a delayed purchase order the way you can push a software update. Raw materials must be on hand before production starts.

Co-leading investors were Carlyle Group (private equity, $475 billion in assets under management), JPMorgan Chase's Strategic Investment Group (led by Todd Combs), and Andreessen Horowitz (venture capital, specifically General Partner Katherine Boyle, who runs a16z's American Dynamism practice). Participating investors included Lightspeed Venture Partners, Lavrock Ventures, Altimeter Capital, General Catalyst, Interlagos Capital, and T. Rowe Price Associates. That last name matters: T. Rowe Price is a public-market crossover fund, which often signals a company is 18-36 months from a public offering.

Who Built Castelion

Castelion was founded in 2022 by three former SpaceX executives: Bryon Hargis (CEO), Sean Pitt, and Andrew Kreitz. Their backgrounds span national-security satellite operations, launch sales, and corporate finance , a deliberate mix built for a company that has to sell to the U.S. government, manufacture hardware, and manage institutional capital simultaneously.

The company's flagship program is Blackbeard, a low-cost hypersonic strike missile. Hypersonic weapons travel at Mach 5 or faster (five times the speed of sound), which makes them extremely difficult to intercept with existing air defense systems. The U.S. military has watched China and Russia field operational hypersonic systems for years while American programs , ARRW, HACM, Conventional Prompt Strike , have faced delays, cost overruns, and test failures. Castelion's pitch is that a SpaceX-style manufacturing approach , rapid iteration, cost discipline, high production volume , can close that gap faster than traditional defense contractors.

SpaceNews reporter Sandra Erwin reported on August 19 that Castelion has existing contracts with the U.S. Department of Defense, though specific contract values and timelines remain classified. That opacity is standard for this sector. It also creates the central risk I'll discuss at the end of this piece.

Why Carlyle and JPMorgan Are Here Now

Carlyle Group is not a venture capital firm. It made its name buying mature businesses, improving operations, and selling them , leveraged buyouts are its core business. So what is Ian Fujiyama, Carlyle's head of its Aerospace, Defense and Government practice, doing co-leading a Series C for a four-year-old startup?

Fujiyama's own words answer the question. He told reporters: "We think there's a multidecade need to rebuild some of that capability that has just atrophied over the years." That framing is important. He is not describing a bet on a single company's product-market fit. He is describing a structural rebuilding of U.S. defense industrial capacity , a thesis with a 20-year horizon that can justify writing checks into early-stage companies where the exit path may be a decade away.

Carlyle also brings something a16z cannot: operational experience with large-scale defense manufacturing, government contracting, and the compliance infrastructure that comes with it. When Castelion eventually needs to navigate ITAR (International Traffic in Arms Regulations , the export control rules governing weapons technology), DCSA facility clearances, and DoD cost accounting standards, having Carlyle's network matters.

JPMorgan's angle is different. Breaking Defense reported in December 2025 that JPMorgan's Security and Resiliency Initiative committed $10 billion over a decade to defense and advanced manufacturing. Todd Combs's Strategic Investment Group is the vehicle. For JPMorgan, this is partly strategic positioning: the bank wants to be the financial partner of record when defense-tech companies eventually go public, issue debt, or get acquired. Co-leading a Series C buys relationship capital that converts to lucrative banking mandates later. That is not cynicism , it is how Wall Street operates, and it is fine as long as you understand the incentive structure.

Castelion vs. Anduril vs. Shield AI: Putting the Numbers in Context

Company	Round	Amount	Valuation	Date	Lead Investors
Castelion	Series C	$1.05B	$13B	Aug 2026	Carlyle, JPMorgan, a16z
Anduril Industries	Series H	$5B	$61B	May 2026	Not publicly specified
Shield AI	Series G	$1.5B	$12.7B	March 2026	Not publicly specified

Anduril's $61 billion Series H valuation from May 2026 reframed what "large" means in defense tech. Palmer Luckey's company sells autonomous weapons systems across a wide portfolio; its diversified revenue base arguably supports a higher multiple. Shield AI, at $12.7 billion in March 2026, focuses on autonomous fighter jet software , a narrower product set than Anduril but a cleaner government-contract-to-revenue story.

Castelion's $13 billion sitting next to Shield AI's $12.7 billion is instructive. These two companies are at roughly equivalent scale by investor perception, despite radically different products. That convergence suggests the market is pricing defense-tech companies on strategic relevance and contract access, not differentiated revenue models. Whether that is wise pricing or hot-money pricing is an open question.

What This Means for Accredited Investors , and the Risks You Cannot Ignore

I want to be direct about something: most individual accredited investors cannot access Castelion directly. The minimum check sizes at this stage run to tens of millions of dollars, and the round is oversubscribed by institutional capital. What you can do is understand the structural shift this deal represents and find your exposure through vehicles that can participate.

The clearest signal here is that defense tech has completed the transition from niche category to institutional asset class. When TechCrunch reported on August 20 that defense tech venture funding in H1 2026 more than doubled to over $12 billion, eclipsing nearly $10 billion for all of 2025, that is not a blip. PitchBook data shows PE investments in global defense and aerospace exceeded $50 billion in 2025. The Carlyle-JPMorgan-a16z tripartite structure on this deal confirms the category has institutional legitimacy it simply did not have three years ago.

For investors evaluating defense-tech exposure, there are real risks on the table that I am not going to paper over.

First, government-contract concentration risk. Castelion's revenue is functionally a single customer: the U.S. Department of Defense. Government budgets shift. Priorities change. The Continuing Resolution problem , where Congress fails to pass an annual defense budget and the military operates on stopgap funding , can delay or freeze program spending unpredictably. A 10% budget cut to hypersonics programs at the DoD could materially impair Castelion's revenue in ways that a commercial SaaS company would never face from a single customer.

Second, hypersonic weapons development timelines and failure rates are brutal. The history of the U.S. hypersonics program is filled with test failures, cost overruns, and schedule delays by experienced defense contractors with billions in existing infrastructure. Castelion's SpaceX-derived manufacturing philosophy is genuinely promising , but "test fast and iterate" works differently when each test article costs millions and certain failure modes are politically visible. A public test failure at the wrong moment can freeze DoD confidence regardless of underlying technical merit.

Third, valuation compression risk is real. Castelion went from a $350 million Series B to a $13 billion Series C in eight months. That 37x step-up reflects urgency-driven institutional FOMO (fear of missing out) as much as it reflects fundamental value creation. Dealroom's coverage of the deal noted the scale of the valuation jump without providing underlying revenue metrics , because Castelion has not disclosed them publicly. Investors buying into defense tech at 2026 multiples should understand they are paying a national-security premium that could compress sharply if the geopolitical urgency that justifies it fades.

Fourth, the Carlyle and JPMorgan presence creates alignment questions worth examining. PE firms earn fees and carried interest. banks earn relationship revenue from future transactions. Neither of those incentive structures is perfectly aligned with long-term company-building. Katherine Boyle at a16z has a cleaner venture incentive structure. Watching how board dynamics play out between these three co-leads as Castelion approaches a liquidity event will matter to eventual public-market investors.

None of these risks mean Castelion is a bad bet. They mean it is a specific bet with specific failure modes, and the investors best positioned to absorb them are large institutions that can diversify across multiple defense-tech positions. For individual accredited investors, the more tractable exposure may be through public defense companies with hypersonics programs, or through defense-tech focused funds with professional due diligence staff and diversified portfolios.

Frequently Asked Questions

What is a revolving credit facility, and why does it matter for a startup?

A revolving credit facility is a flexible line of credit that a company can draw down, repay, and draw down again as cash needs fluctuate , think of it as a corporate credit card with a very large limit. For a hardware company like Castelion that must purchase specialty manufacturing materials before it can invoice the government for finished missiles, the ability to manage working capital timing is critical. without a revolver, even a well-funded company can face cash flow gaps that delay production, and Castelion's inclusion of a $250 million revolver in its Series C signals that institutional lenders view its government contract backlog as creditworthy collateral.

Why would Carlyle Group invest in a four-year-old startup instead of a mature defense company?

Carlyle's Ian Fujiyama framed it as a "multidecade need to rebuild atrophied defense industrial capability" , a thesis that justifies early-stage entry when the asset class has government demand guarantees, and Carlyle brings more than capital to early-stage defense companies: its operational expertise in ITAR compliance, government contracting structures, and large-scale manufacturing gives it an advantage over pure financial investors, which means it can potentially accelerate Castelion's path to DoD production contracts while earning returns that position it at the center of a category it expects to grow for decades.

How does Castelion's $13 billion valuation compare to publicly traded defense contractors?

Traditional defense primes like Raytheon Technologies and Northrop Grumman trade at roughly 1-2x revenue, while Castelion's $13 billion valuation is priced on strategic importance and contract backlog rather than disclosed revenue , meaning investors are paying a significant premium for speed, national-security urgency, and the belief that Castelion's SpaceX-derived manufacturing approach can undercut legacy contractors on cost and timeline. whether that premium is justified depends entirely on whether the company can convert DoD interest into production-scale contracts over the next 24-36 months.

Is there any way for individual accredited investors to get exposure to companies like Castelion?

Direct access to Castelion at this stage is practically unavailable to individual investors given minimum check sizes in the tens of millions, but accredited investors can get adjacent exposure through defense-focused venture funds that invest at earlier stages, through publicly traded defense companies with hypersonics programs, or by watching for secondaries markets where early Castelion investors may eventually offer liquidity. the presence of T. Rowe Price Associates as a participating investor also suggests the company is on a path toward public markets, which would eventually create direct access for retail investors as well.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.